Search

Human fertility is impacted by changes in lifestyle and environmental deterioration. To increase human fertility, assisted reproductive technology (ART) has been extensively used around the globe. As early as 2009, the Endocrine Society released its first scientific statement on the potential adverse effects of environmental endocrine-disrupting chemicals (EDCs) on human health and disease development. Chemicals known as phthalates, frequently employed as plasticizers and additives, are common EDCs. Numerous studies have shown that phthalate metabolites in vivo exert estrogen-like or anti-androgenic effects in both humans and animals. They are associated with the progression of a range of diseases, most notably interference with the reproductive process, damage to the placenta, and the initiation of chronic diseases in adulthood. Phthalates are ingested by infertile couples in a variety of ways, including household products, diet, medical treatment, etc. Exposure to phthalates may exacerbate their infertility or poor ART outcomes, however, the available data on phthalate exposure and ART pregnancy outcomes are sparse and contradictory. Therefore, this review conducted a systematic evaluation of 16 papers related to phthalate exposure and ART pregnancy outcomes, to provide more aggregated results, and deepen our understanding of reproductive outcomes in infertile populations with phthalate exposure., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)

This retrospective study was performed to investigate the predictive power of the Ovarian Sensitivity Index (OSI) for IVF/ICSI outcomes in infertile patients who were of normal expected ovarian response. A total of 912 infertile patients who underwent GnRH antagonist protocol between January 2017 to August 2019 at the Medical Center for Human Reproduction, Beijing Chao-Yang Hospital were included. All patients completed the full oocyte retrieval cycle and either had a live birth or had no embryos left. OSI was significantly lower in patients with a live birth (196.0 ± 120.4 in the live birth group vs 276.4 ± 235.7 in the non-live birth group, p  < 0.001) while follicular output rate (FORT, defined as the ratio of pre-ovulatory follicle count on hCG day x 100/small antral follicle count at baseline) showed no significant difference. Patients were divided into low, average and high OSI groups and analysed in tertiles. From the low to the high OSI group, the cumulative live birth rate (CLBR) decreased dramatically (72.7 vs 67.2 vs 54.8%, p  < 0.001). Multivariate regression analysis showed that OSI was an independent factor affecting CLBR (OR: 0.996, 95%CI: 0.995-0.998, p  < 0.001) in our study population. In conclusion, OSI can be used as an independent indicator to distinguish fecundity in infertile patients with normal expected ovarian response and is probably more sensitive than FORT.

The aim of the study was to examine the clinical value of blastocysts derived from mono-pronuclear (1PN) or non-pronuclear (0PN) zygotes with two polar bodies (2PB), which were selected by our criteria. We retrospectively analysed 610 frozen-thawed blastocyst transfer (FET) cycles and the corresponding oocyte retrieval cycles from 2014 to 2017. Developmental potential and clinical outcomes of embryos derived from zygotes with various numbers of pronuclei were analysed. Based on more detailed pre-selection settings, blastulation rates of 1PN/2PB and 0PN/2PB-derived embryos were 70.18% and 69.17%, respectively. Blastocyst FET results were not significantly different between 2PN/2PB, 1PN/2PB and 0PN/2PB groups in terms of clinical pregnancy rates (59.79%, 47.06% and 56.25%), implantation rates (47.24%, 40.00% and 47.62%), live birth rates (49.39%, 29.41% and 43.75%) or malformation rates (0%, 0% and 0%). In conclusion, after strict morphological selection and blastocyst culture, 1PN/2PB and 0PN/2PB-derived embryos in IVF cycles can have considerable clinical value. Blastocysts derived from 1PN/2PB or 0PN/2PB zygotes are worthwhile FET option for patients who have no available 2PN-derived embryos.

The purpose of this study was to explore the application of glucose to improve embryo development potential when fertilization is delayed in mice. After recovery, mouse oocytes were cultured alone for 6 h before fertilization in three fertilization media: G-IVF PLUS, G-IVF PLUS with 5 mM and 10 mM glucose. G-IVF PLUS group was used as the control group. Then, in vitro fertilization (IVF) was performed and blastocysts were transferred at Day 4. To compare the effects of different glucose concentrations on embryo development and birth outcomes, conventional IVF and embryo transfer were carried out in G-IVF PLUS, G-IVF PLUS with 5 mM and 10 mM glucose. The results indicated that G-IVF PLUS with 5 mM glucose significantly increased blastocyst rate ( p < 0.05) and birth rate ( p < 0.05) when fertilization was delayed 6 h compared with G-IVF PLUS groups. In conventional IVF without delayed fertilization, embryo development was not significantly affected by G-IVF PLUS with 5 mM or 10 mM glucose. There were no significant differences in terms of birth rate, fetal weight, crown-rump length, tail length and birth defect rate among the three groups. In conclusion, 5 mM glucose could significantly improve embryo developmental potential and birth outcomes when fertilization was delayed 6 h and did not have adverse effects on embryo quality and birth outcomes for normal IVF. It might have a good prospect of clinical application in assisted reproductive technology (ART). Abbreviations : ART: assisted reproductive technology; IVF: in vitro fertilization; ICSI: intracytoplasmic sperm injection; TFF: total fertilization failure; TESA: testicular sperm aspiration.

The purpose of this study was to compare the efficacy of different open cryo-carriers: the CryoloopTM, CryotopTM, and CryoleafTM, in embryo survival and clinical outcome in patients with frozen embryo transfer (FET) cycle. We analyzed the embryo survival rate and clinical outcome in 325 patients of 348 FET cycles vitrified with the CryoloopTM (160 cycles), CryotopTM (105 cycles), or CryoleafTM (83 cycles). No significant differences were observed in embryo survival rate (98.8% vs. 100% vs. 97.7%, p > 0.05), HCG positive rate (58.8% vs. 63.8% vs. 57.8%, p > 0.05), biochemical pregnancy rate (6.9% vs. 11.4% vs. 9.6%, p > 0.05), or implantation rate (33.2% vs. 37.4% vs. 34.1%, p > 0.05) in the three groups respectively. The early abortion rate of the CryoloopTM group was significantly higher than that of the CryotopTM and CryoleafTM group (27.1% vs. 3.6% and 7.5%, p < 0.05). At the same time, the average female age of the CryoloopTM group was significantly older by 1 year than that of the CryotopTM and CryoleafTM group (33.29 ± 4.71 years vs. 31.96 ± 4.27 years and 31.1 ± 4.28 years, p < 0.05). There was no significant difference in take home baby rate (38.1% vs. 46.7% vs. 43.4, p > 0.05) or birth weight among the groups (2893.5 ± 780.8 g vs. 2778.4 ± 710.0 g vs. 2724.5 ± 838.8 g, p > 0.05). No case of neonatal malformation was observed in the present study. Overall, CryotopTM and CryoleafTM were effective for embryo vitrification at both the cleavage and blastocyst stage according to the results of clinical outcome and infant characteristics. However, CryoloopTM led to a decreased positive HCG rate and increased early abortion rate, heightened at the cleavage stage., Abbreviations: LN 2 : liquid nitrogen; CPA: cryoprotectant; ART: assisted reproductive technology; IVF: in vitro fertilization; ICSI: intracytoplasmic sperm injection; BMI: body mass index; FSH: follicular stimulation hormone; COH: controlled ovarian hyperstimulation; FET: frozen embryo transfer; mm: millimeter; HCG: human chorionic gonadotropin; RCT: randomized clinical trial; NC: natural cycle; AC: artificial cycle; EM: equilibration medium; DMSO: dimethyl sulphoxide; EG: ethylene glycol; VM: vitrification medium; WM: warming medium.

The aim of this study was to explore whether the morphology of polar bodies (PBs) estimated at 16-18 h after insemination can be used as an additional marker for predicting human embryo quality or pregnancy outcome. The data from 355 patients who received standard in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment after controlled ovarian hyperstimulation were recruited. Normal fertilized 3048 zygotes from 382 cycles were divided into two groups, PBs intact or fragmented, according to the morphology of PBs assessed at 16-18 h after insemination. Embryo quality and pregnancy outcome were compared between the two groups. It was shown that the day 3 (D3) good embryo rate, good quality blastocyst rate and available embryo rate of the PBs intact group were all significantly higher than that of the corresponding fragmented groups. However, no significant differences in pregnancy rate (PR) or implantation rate (IR) were observed between the intact and fragmented groups. Although PBs morphology estimated at 16-18 h after insemination had little effect on PR or IR in fresh embryo transfer cycles, a better embryo quality can be achieved in the PB-intact group, which is valuable for embryo selection.

Objective: To explore the development and pregnancy potential of non-pronuclear (0PN) zygote-derived embryos in conventional in vitro fertilization (IVF) cycles.Study Design: Embryonic development in 1039 oocyte retrieval cycles and clinical outcomes of 659 frozen-thawed blastocyst transfer cycles were retrospectively studied.Results: Developmental potential of embryos with different blastomere numbers on day 3 were inconsistent in 0PN and 2PN groups. For 0PN-derived embryos, blastocyst rate of fast developing embryos (75.4%) was similar to that of intermediately developing embryos (72.9%), but good quality blastocyst rate of the former (49.2%) was significantly higher than that of the later (39.6%). In 2PN group, intermediately developing embryos had the highest blastocyst rate (77.9%) and good quality blastocyst rate (51.5%) (statistically significant). Comparison of frozen-thawed transfer was carried out between 0PN- and 2PN-derived blastocysts. For both single (SBT) and double blastocyst transfer (DBT) groups, no statistical differences existed between 0PN- and 2PN-derived blastocysts in clinical pregnancy rates (45.2% and 49.1% in SBT group, 64.7% and 66.4% in DBT group), implantation rates (45.2% and 49.1% in SBT group, 41.2% and 47.7% in DBT group) and live birth rates (35.5% and 36.8% in SBT group, 52.9% and 51.2% in DBT group).Conclusion: The developmental characteristic of 0PN-derived embryos was different from that of 2PN-derived embryos in IVF cycles. 0PN-derived blastocysts could obtain acceptable clinical pregnancy and live birth, but more studies are needed to confirm the safety.. [ABSTRACT FROM AUTHOR]